Jimo Jian

Dr. Jimo Jian


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HHHongyuan Hao
Hongyuan Hao
CYChenglu Yuan
Chenglu Yuan
CZChen Zhang
Chen Zhang
JJJimo Jian
Jimo Jian
Background: NK-large granular lymphocytic leukemia (NK-LGLL) is a rare clonal lymphoproliferative disease of natural killer (NK) cells. In refractory cases, traditional chemotherapy regimens and immunosuppressive drugs often prove ineffective. Hematopoietic stem cell transplantation (HSCT) offers the opportunity to rebuild the immune system, but carries significant risks, including graft-versus-host disease (GVHD). Consequently, alternative therapeutic strategies need to be investigated. A recent study published in The Lancet reported on the use of golidocitinib in the treatment of relapsed or peripheral T-cell lymphoma. Notably, this represents the first clinical report demonstrating the efficacy of golidocitinib in managing intractable NK-large granular lymphocytic leukemia.Case presentation: In this study, we present a case of a 53-year-old male with NK-LGLL who achieved successful therapeutic outcomes with golidocitinib administration. The patient had a documented history of chronic gastritis and was admitted with symptoms of fatigue and chest tightness. Despite receiving various treatments such as methotrexate, cyclosporin, cyclophosphamide, and thalidomide, the patient exhibited treatment refractoriness. However, after initiating treatment with golidocitinib, the patient’s blood count improved remarkedly after a single treatment cycle, obviating the need for blood transfusions. The patient maintained golidocitinib treatment without experiencing any serious complications. This is the first reported case demonstrating the efficacy of golidocitinib therapy in treating NK-LGLL.Conclusion: This case highlights the clinical relevance of golidocitinib in developing novel therapeutic strategies for NK-LGLL. Moreover, this treatment option presents the potential as either a bridging therapy or alternative to allo-HSCT.

10 March 2023 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
JJJimo Jian
Jimo Jian
NWNana Wang
Nana Wang
HHHongyuan Hao
Hongyuan Hao
CYChenglu Yuan
Chenglu Yuan
QLQian Liu
Qian Liu
FLFei Lu
Fei Lu

1 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JJJimo Jian
Jimo Jian
HHHong-Yuan Hao
Hong-Yuan Hao
CYCheng-Lu Yuan
Cheng-Lu Yuan
SZShu-Qi Zhang
Shu-Qi Zhang
ZHZou-Fang Huang
Zou-Fang Huang
JDJun Du
Jun Du
Indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) is rare, lacking standardized treatments. We report a successful venetoclax treatment in one patient with indolent T-cell lymphoma of the gastrointestinal tract. A 35-year-old male was admitted due to complaints of anemia and hematochezia. He was diagnosed with iTCL-GI according to histopathology and next-generation sequencing (NGS). He received the first cycle of CHOP-E chemotherapy, but he continued to have intermittent blood in stools. After starting oral Bcl-2 inhibitor venetoclax, the results of peripheral hemogram and the body temperature gradually turned normal, with no symptoms of hematochezia occurring again. In addition, colonoscopy showed improved ulcers in the ascending and transverse colon. Routine blood tests returned to normal without adverse effects. Therefore, venetoclax may represent a potential treatment approach for iTCL-GI. This report might provide clues for the future management of similar cases.